Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

ICON Named by Forbes as One of the Best Employers in America


Forbes ranking of top employers drawn from a survey of 30,000 US
employees in 25 industry sectors

, (NASDAQ:ICLR) a global provider of drug development
and commercialisation solutions and services, today announced that it
has been included in Forbes magazine's America's
Best Employers
list for 2018

The Forbes list features the top 500 large employers in the US with more
than 5,000 employees, and the top 500 midsize companies with 1,000 –
5,000 employees. ICON was the highest ranked CRO in the best large
employers listing, and is amongst the top 10 companies in the ‘Drugs &
Biotechnology' industry sector ranking. This is the second consecutive
year that ICON has been the top ranked CRO.

Forbes ‘America's Best Employers List' is determined following an
independent, online survey of almost 30,000 employees at companies with
at least 1,000 people, from 25 industry sectors. The voluntary
participation in online panels allowed employees to share their opinions
about their employers openly and without any influence from their
employer. Respondents were asked to rate their willingness to recommend
their own companies on a scale of 0 – 10, and were also asked to name
good and bad employers in industry sectors other than their own.

"We are proud to be named by Forbes as one of the best employers in
America for the second consecutive year, and to be ranked the top CRO
and amongst the top 10 employers in the Drugs and Biotechnology industry
overall," commented Dr. Steve Cutler, Chief Executive Officer, ICON. "We
are pleased that our employees are recommending ICON as an excellent
place to work. We have great people who are committed to helping our
clients to accelerate the development of drugs and devices that are
saving lives and improving the quality of life of patients right across
the globe. We will continue to work hard to ensure that we provide a
work environment that engages, rewards and develops our employees so
that they can build successful careers at ICON."

About ICON
ICON plc is a global provider of outsourced drug
development and commercialisation solutions and services to
pharmaceutical, biotechnology, medical device, and government and public
health organisations. The company specialises in the strategic
development, management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical studies.
With headquarters in Dublin, Ireland, ICON currently, operates from 98
locations in 38 countries and has approximately 13,380 employees.
Further information is available at

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at


View Comments and Join the Discussion!